Mabtech AB

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Mabtech AB - overview

Established

1986

Location

Stockholm, -, Sweden

Primary Industry

Biotechnology

About

Based in Nacka Strand, Sweden, and founded in 1986, Mabtech AB operates as a provider of monoclonal antibodies, kits, and instruments for immunoassays to the life sciences research community. In January 2024, EQT agreed to acquire Mabtech AB from IK Partners and Merieux Equity Partners. As of 2024, the company is led by its CEO, Phill Keefe. The company provides a wide range of immunoassay products, such as ELISpot kits, FluoroSpot kits, ELISA kits, and FociSpot assays.


Additionally, the firm offers Mabtech IRISTM 2 and Mabtech ASTORTM 2 readers, peptide pools, polyclonal stimuli, buffers, substrates, plates, and antibodies. The company generates revenue through the sale of its immunoassay products through its e-commerce platform.


Current Investors

IK Partners, Merieux Equity Partners

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Medical Equipment Distributors

Website

www.mabtech.com/

Verticals

E-commerce, HealthTech

Company Stage

Mature - Buyout

Total Amount Raised

Subscriber access only

Mabtech AB - deals

Deals TypeDeal StatusTarget (s)Deal DateInvestor(s)Seller(s)Deal size (Mn)Enterprise value (Mn)Post-money valuation (Mn)EBITDA multiple (x)Revenue multiple (x)Lead partner (s)
Secondary BuyoutCompletedMabtech AB-
BuyoutCompletedMabtech AB-

Displaying 1 - 2 of 2

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.